Category: Pakistan

Posted on

ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – NTLA

NEW YORK, March 16, 2025 (GLOBE NEWSWIRE) —

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Intellia Therapeutics, Inc. (NASDAQ: NTLA) between July 30, 2024 and January 8, 2025, both dates inclusive (the “Class Period”), of the important April 14, 2025 lead plaintiff deadline.

SO WHAT: If you purchased Intellia securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Intellia class action, go to   https://rosenlegal.com/submit-form/?case_id=35009 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 14, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants provided investors with material information concerning Intellia’s Phase 1/2 study evaluating NTLA-3001 for the treatment of alpha-1 antitrypsin deficiency (AATD)-associated lung disease. Defendants’ statements included, among other things, confidence in Intellia’s timeline for the aforementioned study, specifically that Intellia expected to dose the first patient in the second half of 2024. Defendants failed to disclose inter alia that the demand for viral-based editing was rapidly dwindling as non-viral delivery methods became a main target of the scientific research community due to their cost-effectiveness and more efficient development, thus making NTLA-3001 an inefficient program for Intellia to maintain. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Intellia class action, go to https://rosenlegal.com/submit-form/?case_id=35009 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com

GlobeNewswire Distribution ID 9394814

Posted on

FTAI DEADLINE TUESDAY: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages FTAI Aviation Ltd. Investors to Secure Counsel Before Important March 18 Deadline in Securities Class Action – FTAI

NEW YORK, March 16, 2025 (GLOBE NEWSWIRE) —

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of FTAI Aviation Ltd. (NASDAQ: FTAI) between July 23, 2024, and January 15, 2025, both dates inclusive (the “Class Period”), of the important March 18, 2025 lead plaintiff deadline.

SO WHAT: If you purchased FTAI securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the FTAI class action, go to https://rosenlegal.com/submit-form/?case_id=33693 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than March 18, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants, throughout the Class Period, failed to disclose to investors that: (1) FTAI reported one-time engine sales as Maintenance Repair & Overhaul revenue when FTAI only performs limited repair and maintenance work on the engine assets sold; (2) FTAI presents whole engine sales as individual module sales, thereby overstating sales and demand; and (3) FTAI depreciates engines that are not on lease, which misleadingly lowers the reported cost of goods sold and inflates EBITDA. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the FTAI class action, go to https://rosenlegal.com/submit-form/?case_id=33693 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

——————————-

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com

GlobeNewswire Distribution ID 9394786

Posted on

IIPR FINAL DEADLINE: ROSEN, A LONGSTANDING LAW FIRM, Encourages Innovative Industrial Properties, Inc. Investors to Secure Counsel Before Important March 18 Deadline in Securities Class Action — IIPR

NEW YORK, March 16, 2025 (GLOBE NEWSWIRE) —

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Innovative Industrial Properties, Inc. (NYSE: IIPR) between February 27, 2024 and December 19, 2024, both dates inclusive (the “Class Period”), of the important March 18, 2025 lead plaintiff deadline.

SO WHAT: If you purchased IIPR securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the IIPR class action, go to https://rosenlegal.com/submit-form/?case_id=33890 or call Phillip Kim, Esq. at 866-767-3653 or email [email protected] for more information. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than March 18, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and misleading statements and/or failed to disclose that: (1) IIPR was experiencing significant declines in rent and property-management fees in connection with certain customer leases; (2) the foregoing would likely impair IIPR’s ability to maintain funds from operations (“FFO”) and revenue growth; (3) accordingly, IIPR’s leasing operations were less profitable than IIPR had represented to investors; and (4) as a result, IIPR’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the IIPR class action, go to https://rosenlegal.com/submit-form/?case_id=33890 or call Phillip Kim, Esq. at 866-767-3653 or email [email protected] for more information.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com

GlobeNewswire Distribution ID 9394790

Posted on

CGTN: Two years on, China’s Global Civilization Initiative gains greater relevance in a turbulent world

CGTN published an article on the second anniversary of China’s Global Civilization Initiative proposed by Chinese President Xi Jinping, which has become more relevant than ever amid uncertainty, turbulence and division in current times. Through introducing China’s efforts to practice the initiative and insights provided by experts and scholars, the article emphasized that China’s respect for the diversity of civilizations makes the country an important role model for promoting world peace and stability.

BEIJING, March 15, 2025 (GLOBE NEWSWIRE) — Two years ago, Chinese President Xi Jinping introduced the Global Civilization Initiative (GCI), calling for respect for cultural diversity, the promotion of common human values, the preservation and innovation of civilizations, and stronger international people-to-people exchanges.

In today’s world, the initiative has become more relevant than ever amid uncertainty, turbulence, and division.

Facing rising anti-globalization trends, Elias Jabbour, a professor at the State University of Rio de Janeiro’s Faculty of Economic Sciences, highlighted the growing significance of GCI. He said China’s inclusive approach to diversity sets an example for the world. At a time when some self-proclaimed “civilized” nations are enforcing mass deportations and repatriations, China’s emphasis on mutual respect and cultural exchange stands in sharp contrast, the professor said, while commending the GCI for championing the coexistence of diverse civilizations without imposing one nation’s values on another.

Guiding the world toward peace

When Xi proposed GCI at the CPC in Dialogue with World Political Parties High-Level Meeting in March 2023, he quoted a Chinese proverb: “A single flower does not make spring, while one hundred flowers in full blossom bring spring to the garden” to indicate the vitality of cultural diversity and the necessity of embracing multiple civilizations in building a harmonious world.

“Countries need to uphold the principles of equality, mutual learning, dialogue and inclusiveness among civilizations, and let cultural exchanges transcend estrangement, mutual learning transcends clashes, and coexistence transcend feelings of superiority,” said Xi.

China’s commitment to civilization dialogue was recognized later in June when the UN adopted a resolution proposed by China, designating June 10 as the International Day for Dialogue among Civilizations. Chinese envoy to the UN, Fu Cong, stated that this initiative sought to refocus global attention on intercultural dialogue at a “critical juncture.”

“If you look around the world, you see a lot of disputes, a lot of conflicts or even wars. And also, there is a surge of intolerance, extremism and also populism. All these can find their roots in the differences or the lack of understanding among cultures and religions,” Fu said.

A CGTN poll of 15,574 people across 40 countries and regions, published in March 2023, found that 80.3 percent see multiple civilizations as beneficial to global development, 85 percent believe in building a shared future through tolerance and cooperation, while 89.6 percent call for greater dialogue and openness, rising to 93.7 percent in developing countries.

Actions speak louder than words

China is not just an advocate, but also a true practitioner.

In November 2023, Beijing hosted the first World Conference of Classics, where over 400 experts engaged in discussions on classical civilizations. The conference was a platform to encourage nations to draw wisdom from ancient traditions, fostering greater mutual understanding. Since then, China has organized international forums such as the Nishan Forum on World Civilizations and the International Chinese Language Conference, which bring together scholars, policymakers, and cultural experts to explore shared values.

Cultural preservation is one of the main aspects of China’s commitment to the initiative. The Beijing Central Axis, a historic architectural complex dating back to the Yuan Dynasty (1271-1368), was officially inscribed as a UNESCO World Heritage Site in 2024. The same year, the Chinese Spring Festival was added to UNESCO’s Representative List of Intangible Cultural Heritage of Humanity. These milestones underscore China’s dedication to safeguarding and promoting its rich cultural legacy on the global stage.

The country has been actively exploring and promoting elements of traditional Chinese culture, bringing its charm to the global stage. From the animated film Ne Zha 2 topping the global box office for animated films, to the video game Black Myth: Wukong gaining international popularity, and the dance drama Wing Chun becoming a smash hit in overseas markets, China is continuously innovating its cultural heritage.

It has also made efforts to strengthen people-to-people exchanges. Over the past year, student groups from cities such as Dallas, Houston, New York, and San Francisco have traveled to China to visit universities, companies, and iconic landmarks, following President Xi’s 2023 pledge to invite 50,000 students over five years. In recent years, China has co-hosted “Tourism Years” with multiple countries to promote cultural exchange. By the end of 2024, China had expanded its visa-free entry policy to 29 countries, including France, Germany and Italy, facilitating greater global connections.

For more information, please click:
https://news.cgtn.com/news/2025-03-15/Two-years-on-China-s-GCI-becomes-more-vital-in-turbulent-times-1BL2FHhmmaY/p.html

Email: [email protected]

GlobeNewswire Distribution ID 9395124

Posted on

Nyxoah Reports Fourth Quarter and Financial Year 2024 Financial and Operating Results

REGULATED INFORMATION

Nyxoah Reports Fourth Quarter and Financial Year 2024 Financial and Operating Results
FDA PMA Application Review Nearing Conclusion
Positioned for U.S. Commercial Launch in March 2025

Mont-Saint-Guibert, Belgium – March 13, 2024, 7:00am CET / 2:00am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today reported financial and operating results for the fourth quarter and financial year 2024.

Recent Financial and Operating Highlights

  • Revenue for the fourth quarter of 2024 was €1.3 million, which excludes €0.6 million of deferred revenue
  • Revenue for the full year 2024 was €4.5 million, which excludes €0.6 million of deferred revenue
  • Gross margin for the fourth quarter of 2024 was 73%
  • At December 31, 2024, cash and financial assets were €85.6 million, compared to €57.7 million at December 31, 2023
  • Assembled U.S. executive leadership team with deep industry experience
  • Full U.S. commercial organization, including sales, marketing, and market access teams, in place

“2024 was a transformative year for Nyxoah. We reported best-in-class outcomes from our DREAM pivotal study, completed our PMA submission with the FDA for Genio, and built a world-class U.S. commercial organization,” commented Olivier Taelman, Nyxoah’s Chief Executive Officer. “We believe an approval is still expected by the end of the first quarter, and we look forward to launching this innovative therapy to the millions of Americans suffering from moderate to severe OSA.”

Fourth Quarter and Full Year 2024 Results

Revenue

In the fourth quarter of 2024, the Company began recording a portion of the selling price for a Genio system related to disposable patches as deferred revenue and recognized €0.6 million in the quarter. Due to this deferral, reported revenue was €1.3 million for the fourth quarter ending December 31, 2024, and €4.5 million for the full year. Had the Company not recorded deferred revenue for its disposable patches, total revenue for the fourth quarter would have €1.9 million, up 46% versus the third quarter of 2024. Likewise, revenue for the full year 2024 would have been €5.1 million, up 18% from €4.3 million in 2023. The increase in full year revenue was attributable to the Company’s commercialization of the Genio® system, primarily in Germany.

Cost of Goods Sold

Cost of goods sold was €0.3 million for the three months ending December 31, 2024, representing a gross profit of €0.9 million, or gross margin of 73%. This compares to total cost of goods sold of €0.7 million in the fourth quarter of 2023, for a gross profit of €1.1 million, or gross margin of 60%.

For the full year ending December 31, 2024, total cost of goods sold was €1.5 million, representing a gross profit of €3.0 million, or gross margin of 66%. This compares to total cost of goods sold of €1.7 million for the full year of 2023, for a gross profit of €2.7 million, or gross margin of 62%.

Research and Development
For the fourth quarter ending December 31, 2024, research and development expenses were €11.7 million, versus €7.3 million for the fourth quarter ending December 31, 2023. For the full year ending December 31, 2024, research and development expenses were €34.3 million, versus €26.7 million for the full year of 2023. The increase in research and development expenses was primarily driven by higher R&D activities and clinical expenses.

Selling, General and Administrative
For the fourth quarter ending December 31, 2024, selling, general and administrative expenses were €8.1million, versus €4.9 million for the fourth quarter ending December 31, 2023. For the full year ending December 31, 2024, selling, general and administrative expenses were €28.5 million, versus €21.7 million for the full year of 2023. The increase in selling, general and administrative expenses was mainly due to an increase of costs to support the commercialization of Genio® system in Europe and scale up of the Company.

Operating Loss
Total operating loss for the fourth quarter and full year 2024 was €18.3 million and €58.8 million, respectively, versus €10.8 million and €45.1 million in the fourth quarter and full year 2023, respectively. This was driven by the acceleration in the Company’s R&D spending, as well as ongoing commercial and clinical activities.

Cash Position
As of December 31, 2024, cash and financial assets totaled €85.6 million, compared to €57.7 million on December 31, 2023.

Annual Report 2024
Nyxoah is currently finalizing the financial statements for the year ended December 31, 2024. The Company’s independent auditor has confirmed that their audit procedures, which have been substantially completed, have not revealed any material adjustments which would have to be made to the accounting information included in this press release. The complete consolidated financial statements for the year ended December 31, 2024 as well as the complete audit report related to the audit of the consolidated financial statements will be included in the 2024 Annual Report which the Company aims to publish on or around March 20, 2025. When published, the Nyxoah Annual Report for the financial year 2024 will be available on the investor page of Nyxoah’s website (https://investors.nyxoah.com/financials).

Conference call and webcast presentation
Company management will host a conference call to discuss financial results on Thursday, March 13, 2025, beginning at 1:00pm CET / 8:00am ET.

A webcast of the call will be accessible via the Investor Relations page of the Nyxoah website or through this link: Nyxoah’s Q4 and FY 2024 Earnings Call Webcast. For those not planning to ask a question of management, the Company recommends listening via the webcast.

If you plan to ask a question, please use the following link: Nyxoah’s Q4 and FY 2024 Earnings Call. After registering, an email will be sent, including dial-in details and a unique conference call access code required to join the live call. To ensure you are connected prior to the beginning of the call, the Company suggests registering a minimum of 10 minutes before the start of the call.

The archived webcast will be available for replay shortly after the close of the call.

CONSOLIDATED STATEMENTS OF LOSS AND OTHER COMPREHENSIVE LOSS (unaudited)
(in thousands)

  For the three months ended December 31,   For the twelve months ended December 31,
  2024   2023   2024   2023
Revenue 1 263   1 824   4 521   4 348
Cost of goods sold (335)   (726)   (1 552)   (1 656)
Gross profit € 928   € 1 098   € 2 969   € 2 692
Research and Development Expense (11 752)   (7 321)   (34 325)   (26 651)
Selling, General and Administrative Expense (8 065)   (4 893)   (28 461)   (21 687)
Other income/(expense) 578   279   1 008   544
Operating loss for the period €(18 311)   €(10 837)   €(58 809)   €(45 102)
Financial income 2 832   582   7 447   4 174
Financial expense 410   (964)   (5 070)   (3 729)
Loss for the period before taxes €(15 069)   €(11 219)   €(56 432)   €(44 657)
Income taxes (2 080)   326   (2 804)   1 445
Loss for the period €(17 149)   €(10 893)   €(59 236)   €(43 212)
               
Loss attributable to equity holders €(17 149)   €(10 893)   €(59 236)   €(43 212)
               
Other comprehensive income/(loss)              
Items that may not be subsequently reclassified to profit or loss (net of tax)              
Remeasurements of post-employment benefit obligations, net of tax 11   81

11

81
Items that may be subsequently reclassified to profit or loss (net of tax)      

 

 
Currency translation differences 545   (32)

766

(120)
Total other comprehensive income/(loss) €556   €(39)   €777   €(39)
Total comprehensive loss for the year, net of tax €(16 151)   € (10 844)   €(58 459)   €(43 251)
Loss attributable to equity holders €(16 151)   € (10 844)   €(58 459)   €(43 251)
               
Basic loss per share (in EUR) €(463)   €(379)   €(1 809)   €(1 545)
Diluted loss per share (in EUR) €(463)   €(379)   €(1 809)   €(1 545)
CONSOLIDATED BALANCE SHEET (unaudited)
(in thousands)
      As at December 31
      2024   2023
ASSETS          
Non-current assets          
Property, plant and equipment     4 753   4 188
Intangible assets     50 381   46 608
Right of use assets     3 496   3 788
Deferred tax asset     76   56
Other long-term receivables     1 617   1 166
      € 60 323   € 55 806
Current assets          
Inventory     4 716   3 315
Trade receivables     3 382   2 758
Other receivables     2 774   3 212
Other current assets     1 656   1 318
Financial assets     51 369   36 138
Cash and cash equivalents     34 186   21 610
      € 98 083   € 68 351
Total assets     € 158 406   € 124 157
           
EQUITY AND LIABILITIES          
Share capital and reserves          
Share capital     6 430   4 926
Share premium     314 345   246 127
Share based payment reserve     9 300   7 661
Other comprehensive income     914   137
Retained loss     (217 735)   (160 829)
Total equity attributable to shareholders     € 113 254   € 98 022
           
LIABILITIES          
Non-current liabilities          
Financial debt     18 725   8 373
Lease liability     2 562   3 116
Pension liability     −   9
Provisions     1 000   185
Deferred tax liability     19   9
Contract liability     472   −
Other liabilities     845   −
      € 23 623   € 11 692
Current liabilities          
Financial debt     248   364
Lease liability     1 118   851
Trade payables     9 505   8 108
Current tax liability     4 317   1 988
Contract liability     117   −
Other liabilities     6 224   3 132
      € 21 529   € 14 443
Total liabilities     € 45 152   € 26 135
Total equity and liabilities     € 158 406   € 124 157

About Nyxoah
Nyxoah is reinventing sleep for the billion people that suffer from obstructive sleep apnea (OSA). We are a medical technology company that develops breakthrough treatment alternatives for OSA through neuromodulation. Our first innovation is Genio®, a battery-free hypoglossal neuromodulation device that is inserted through a single incision under the chin and controlled by a wearable. Through our commitment to innovation and clinical evidence, we have shown best-in-class outcomes for reducing OSA burden.

Following the successful completion of the BLAST OSA study, the Genio® system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study for FDA and U.S. commercialization approval.

For more information, please visit http://www.nyxoah.com/.

Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.

Forward-looking statements

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company’s or, as appropriate, the Company directors’ or managements’ current expectations regarding the Genio® system; planned and ongoing clinical studies of the Genio® system; the potential advantages of the Genio® system; Nyxoah’s goals with respect to the development, regulatory pathway and potential use of the Genio® system; the utility of clinical data in potentially obtaining FDA approval of the Genio® system; receipt of FDA approval; entrance to the U.S. market; and the Company’s results of operations, financial condition, liquidity, performance, prospects, growth and strategies. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. Additionally, these risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2023, filed with the Securities and Exchange Commission (“SEC”) on March 20, 2024, and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

Contacts:

Nyxoah
John Landry – CFO
[email protected]

For Media
United States
FINN Partners – Glenn Silver
[email protected]

Belgium/France
Backstage Communication – Gunther De Backer
[email protected]

International/Germany
MC Services – Anne Hennecke
[email protected]

Attachment

GlobeNewswire Distribution ID 1001053522

Posted on

Facephi accelerates the digitalization of the air travel with verified identity and its KYP (Know Your Passenger) solution at the IATA World Data Symposium

KYP IATA Facephi digital Identity seamless travel

Facephi accelerates the digitalization of the air travel with verified identity and its KYP (Know Your Passenger) solution

MADRID, March 12, 2025 (GLOBE NEWSWIRE) — Facephi, a leading company in digital identity technology, has reinforced its commitment to transforming the aviation sector at the IATA World Data Symposium. At this key industry event, the company showcased several solutions aimed at enabling a fully digital air travel experience, aligning with IATA’s One ID initiative, which seeks to eliminate airport frictionless through verifiable credentials and facial biometrics.

Currently, passengers must verify their identity at multiple checkpoints throughout a single journey, leading to delays and increased congestion at airports. To address this challenge, Facephi has developed technology that enables identity validation before arriving at the airport, reducing wait times and ensuring a seamless and secure travel experience. This innovation has already been successfully tested in collaboration with IATA through a proof of concept conducted last November.

A privacy-first approach that empowers the user

Complementing other solutions that have proven to reduce processing times by 40%, Facephi advocates for a decentralized model that enhances security and privacy. By leveraging verifiable credentials (VCs) and secure digital wallets, passengers have full control over when and how they share their personal information, ensuring compliance with global data protection regulations.

Facephi’s approach integrates advanced biometric verification with strong customer authentication (SCA) technologies, enabling fast, contactless identification at every checkpoint. From passport scanning to generating a Type 1 Digital Travel Credential (DTC) and creating verifiable credentials, travelers can securely store and manage their digital identity, streamlining check-in, security checks, and boarding processes.

Setting new standards for interoperability

By aligning with IATA’s core principles, Facephi ensures interoperability standards between airlines, airports, and government authorities.

With the creation of VCs at a Level of Assurance High (Immigration Level) that can be used by government entities, Facephi reaffirms its leadership in aviation digitalization.

The company’s strong commitment to this industry translates into innovative solutions that not only optimize operational efficiency at airports but also empower passengers by giving them greater control over their digital identity.

Know more: https://en.facephi.com/seamless-travel-experience/

Contact Details: [email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/a624234b-1707-4fec-912d-d5ec321b031c

GlobeNewswire Distribution ID 1001053449